XML 33 R22.htm IDEA: XBRL DOCUMENT
v3.26.1

COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK | 3 Months Ended
--- | ---
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract] |
COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK | NOTE 15 – COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK Options 2026 During the three months ended March 31, 2026, the Company’s Board of Directors granted 5,000 5 year stock options with a strike price of $11.44 per share to one key employee. These options were awarded as a one-time award as a retention incentive and have a fair value of $40,948 and carry a three-year vesting period.
Schedule of options activity |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (Years) |  |  | Aggregate Intrinsic Value |
| Outstanding at December 31, 2024 |  |  |  | 606,452 |  |  | $ | 5.29 |  |  |  | 2.0 |  |  | $ | 514,394 |
| Granted |  |  |  | 20,000 |  |  | $ | 5.64 |  |  |  | 2.5 |  |  | $ | 112,200 |
| Forfeited |  |  |  | (271,449 | ) |  | $ | 5.71 |  |  |  | — |  |  | $ | — |
| Outstanding at December 31, 2025 |  |  |  | 355,003 |  |  | $ | 5.00 |  |  |  | 1.8 |  |  | $ | 2,219,665 |
| Exercisable at December 31, 2025 |  |  |  | 283,000 |  |  | $ | 5.15 |  |  |  | 1.5 |  |  | $ | 1,727,688 |
| Outstanding at December 31, 2025 |  |  |  | 355,003 |  |  | $ | 5.00 |  |  |  | 1.8 |  |  | $ | 2,219,665 |
| Granted |  |  |  | 5,000 |  |  | $ | 11.44 |  |  |  | 4.8 |  |  | $ | — |
| Exercised |  |  |  | (15,000 | ) |  | $ | 4.69 |  |  |  | — |  |  | $ | — |
| Forfeited/Expired |  |  |  | (20,000 | ) |  | $ | 4.18 |  |  |  | — |  |  | $ | — |
| Outstanding at March 31, 2026 |  |  |  | 325,003 |  |  | $ | 5.16 |  |  |  | 1.8 |  |  | $ | 575,104 |
| Exercisable at March 31, 2026 |  |  |  | 251,334 |  |  | $ | 5.24 |  |  |  | 1.5 |  |  | $ | 408,018 |
The fair value of the incentive stock option grants for the three months ended March 31, 2026 and 2025 were estimated using the following assumptions:
Schedule of fair value of warrants |  |  |  |  |  |
|  | For the Three Months Ended March 31, |
|  | 2026 |  |  | 2025 |
Stock price |  | $ | 11.25 |  |  | $ | — |
Exercise Price |  | $ | 11.44 |  |  | $ | — |
Risk free interest rate |  |  | 3.55 | % |  |  | — |
Expected term in years |  |  | 5 |  |  |  | — |
Dividend yield |  |  | — |  |  |  | — |
Volatility of common stock |  |  | 93.67 | % |  |  | — |
Weighted average grant date fair value per option was $8.19 for the three months ended March 31, 2026. Warrants 2026 In connection with the Company’s equity financing completed during the quarter ended March 31, 2026, the Company issued 5-year warrants for 433,334 common shares at an exercise price of $9.00 per share to the investment bankers who facilitated the offering. The warrants were issued contemporaneously with the closing of the financing and were included as part of the negotiated engagement terms. The warrants are indexed to the Company’s common stock, provide for settlement in a fixed number of shares for a fixed exercise price, and are freestanding equity instruments. Accordingly, they meet the criteria for equity classification under ASC 815-40 and are not subject to remeasurement in future periods. The Company determined the warrants were non-compensatory pursuant to ASC 340-10-S99-1, as they were issued as part of the overall consideration for services directly related to the capital raise, were not tied to future performance, and did not include any vesting or service conditions. The fair value of the warrants was determined using the Black-Scholes option-pricing model based on the following key assumptions: expected volatility, risk-free interest rate, expected term, and expected dividend yield as of the grant date. The resulting fair value of approximately $2,305,016 was recorded as a reduction to Additional Paid-In Capital (APIC) within stock issuance costs, with a corresponding credit to APIC for the issuance of the warrants. The Company used the following assumptions in determining the fair value of the warrants:
Schedule of assumptions |  |  |
Date of Grant |  | March 2, 2026 |
Stock Price |  | $ | 7.61 |
Exercise Price |  | $ | 9.00 |
Expected Remaining Term (Years) |  |  | 5.00 |
Expected Volatility |  |  | 92 | %
Dividend Yield |  |  | 0 | %
Discount Rate - Bond Equivalent Yield |  |  | 3.620 | %
No income statement impact is expected related to these warrants in future periods.
Schedule of warrants outstanding |  |  |  |  |  |  |  |  |  |  |  |
|  | Number of Warrants |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (Years) |  |  | Aggregate Intrinsic Value |
Outstanding at December 31, 2024 |  |  | — |  |  | $ | — |  |  |  | — |  |  | $ | — |
Warrants expired, forfeited, cancelled or exercised |  |  | — |  |  | $ | — |  |  |  | — |  |  | $ | — |
Warrants issued |  |  | 375,276 |  |  | $ | 7.20 |  |  |  | 5.0 |  |  | $ | — |
Outstanding at December 31, 2025 |  |  | 375,276 |  |  | $ | 7.20 |  |  |  | 4.6 |  |  | $ | 1,519,868 |
Exercisable at December 31, 2025 |  |  | 375,276 |  |  | $ | 7.20 |  |  |  | 4.6 |  |  | $ | 1,519,868 |
Outstanding at December 31, 2025 |  |  | 375,276 |  |  | $ | 7.20 |  |  |  | 4.6 |  |  | $ | 1,519,868 |
Warrants expired, forfeited, cancelled or exercised |  |  | — |  |  | $ | — |  |  |  | — |  |  | $ | — |
Warrants issued |  |  | 433,334 |  |  | $ | 9.00 |  |  |  | 5.0 |  |  | $ | — |
Outstanding at March 31, 2026 |  |  | 808,610 |  |  | $ | 8.16 |  |  |  | 4.7 |  |  | $ | — |
Exercisable at March 31, 2026 |  |  | 808,610 |  |  | $ | 8.16 |  |  |  | 4.7 |  |  | $ | — |
Restricted Stock
Schedule of restricted stock |  |  |  |  |  |
|  | Number of Shares |  |  | Weighted Average Grant Date Fair Value Per Share |
Unvested at December 31, 2024 |  |  | — |  |  | $ | — |
Restricted stock granted |  |  | 2,146,898 |  |  | $ | 6.13 |
Restricted stock forfeited |  |  | (162,500 | ) |  | $ | 6.00 |
Restricted stock vested |  |  | (20,000 | ) |  | $ | 5.22 |
Unvested at December 31, 2025 |  |  | 1,964,398 |  |  | $ | 6.15 |
Vested at December 31, 2025 |  |  | 20,000 |  |  | $ | 5.22 |
Unvested at December 31, 2025 |  |  | 1,964,398 |  |  | $ | 6.15 |
Restricted stock granted |  |  | 420,000 |  |  | $ | 10.70 |
Restricted stock forfeited |  |  | — |  |  | $ | — |
Restricted stock vested |  |  | (10,000 | ) |  | $ | 5.98 |
Unvested at March 31, 2026 |  |  | 2,374,398 |  |  | $ | 6.95 |
Vested at March 31, 2026 |  |  | 30,000 |  |  | $ | 5.47 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration